Back to top
more

Centene (CNC)

(Delayed Data from NYSE)

$25.89 USD

25.89
17,010,329

-0.32 (-1.22%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $25.86 -0.03 (-0.12%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 1% (244 out of 246)

Industry: Medical - HMOs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Centene Corporation is a well-diversified, multi-national healthcare company that primarily provides a set of services to the government sponsored healthcare programs. The company serves the under-insured and uninsured individuals through member-focused services. It is also engaged in providing education and outreach programs to inform and assist members in accessing quality, appropriate healthcare services. Centene is now a $100-billion plus enterprise catering healthcare services to more than 24 million members across 50 states. The recent acquisition of WellCare Health leveraged the company’s position as the largest Medicaid managed care organization in the country. The combined entity now has 22 million members. In 2019, the company retained its market-leading position nationwide, serving 1.8 million exchange members across 20 states at the year-end.

Zacks Equity Research

Why Is Centene (CNC) Down 2.6% Since its Last Earnings Report?

by Zacks Equity Research

Centene (CNC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Zacks Equity Research

    The Zacks Analyst Blog Highlights: Centene, Macy's, LyondellBasell, Huntington Ingalls and Lam Research

    by Zacks Equity Research

    The Zacks Analyst Blog Highlights: Centene, Macy's, LyondellBasell, Huntington Ingalls and Lam Research

      Zacks Equity Research

      3 Reasons Why You Should Invest in athenahealth (ATHN) Stock

      by Zacks Equity Research

      athenahealth (ATHN) rides on solid fourth-quarter results and strong fundamentals.

        Swarup Gupta headshot

        Are Tariff War Fears Overblown? 5 Great Value Choices

        by Swarup Gupta

        Trump's NAFTA related comments show that the President is yet to make up his mind on tariff-related announcements.

          Zacks Equity Research

          ResMed (RMD) Rides High on Robust Global Growth & Innovation

          by Zacks Equity Research

          ResMed (RMD) consistently invests and expands globally in high-growth markets like China, South Korea, India, Brazil and across the Eastern Europe belt.

            Zacks Equity Research

            Varian (VAR) Rides on Diverse Product Line, Competition Rife

            by Zacks Equity Research

            Varian Medical (VAR) has a strong international presence and growing proton therapy market. However, intense competition adds to woes.

              Zacks Equity Research

              Stryker Closes Entellus Buyout, Bolsters Neurotechnology Line

              by Zacks Equity Research

              Stryker (SYK) maintains its acquisition-driven strategy to provide superior and more economic patient experiences.

                Zacks Equity Research

                Cardiovascular Systems Gains From 510K for OrbusNeich Device

                by Zacks Equity Research

                Cardiovascular Systems (CSII) to distribute limited editions of both 1.0-4.0mm Sapphire II PRO and 2.0-4.0mm Sapphire NC Plus non-compliant coronary balloons post the product launches in the market.

                  Zacks Equity Research

                  Universal Health (UHS) Q4 Earnings, Revenues Beat Estimates

                  by Zacks Equity Research

                  Solid segmental performance drives Universal Health's (UHS) fourth-quarter results.

                    Zacks Equity Research

                    Community Health's (CYH) Q4 Loss Narrower Than Expected

                    by Zacks Equity Research

                    Lower admission hurts Community Health's (CYH) fourth-quarter results.

                      Zacks Equity Research

                      Veeva Systems (VEEV) Q4 Earnings Top, FY19 View Promising

                      by Zacks Equity Research

                      Veeva Systems (VEEV) continues to witness year-over-year growth on earnings and revenues backed by the company's consistent efforts in product innovation and launches via R&D.

                        Zacks Equity Research

                        Zacks.com highlights: Centene, Andersons, Builders FirstSource, United Continental Holdings and Dillard's

                        by Zacks Equity Research

                        Zacks.com highlights: Centene, Andersons, Builders FirstSource, United Continental Holdings and Dillard's

                          Zacks Equity Research

                          Envision Healthcare (EVHC) Q4 Earnings Beat, Revenues Rise

                          by Zacks Equity Research

                          Envision Healthcare (EVHC) earnings benefited from higher revenues partly offset by an increase in expenses.

                            Zacks Equity Research

                            Allscripts' (MDRX) Fundamentals Strong Amid Stiff Competition

                            by Zacks Equity Research

                            Allscripts' (MDRX) promising fourth-quarter results and international hold are encouraging. Integration risks and cutthroat competition are likely to mar prospects.

                              Zacks Equity Research

                              Masimo Products to Boost India-Based NU Hospitals' Systems

                              by Zacks Equity Research

                              Masimo's (MASI) flagship technologies to be incorporated in India-based NU Hospitals' continuum of care.

                                Zacks Equity Research

                                Tenet Healthcare (THC) Q4 Earnings & Revenues Top Estimates

                                by Zacks Equity Research

                                Strong segmental performances along with solid expense management aid Tenet Healthcare's (THC) Q4.

                                  Zacks Equity Research

                                  5 Stocks to Bet on Following Recent Broker Rating Upgrades

                                  by Zacks Equity Research

                                  With multiple earnings reports flooding the market, determining the outperformers is by no means an easy task for individual investors.

                                    Zacks Equity Research

                                    LifePoint Health (LPNT) Q4 Earnings Miss on Lower Revenues

                                    by Zacks Equity Research

                                    LifePoint Health (LPNT) fails to beat the earnings and revenue estimates in the fourth quarter. Equivalent admissions decline 3% year over year.

                                      Zacks Equity Research

                                      Here's Why You Must Add Haemonetics (HAE) to Your Portfolio

                                      by Zacks Equity Research

                                      Haemonetics (HAE) delivers strong plasma revenues, driven by a robust performance in disposables and software in the United States. Also, the market seems upbeat about this new PCS platform.

                                        Zacks Equity Research

                                        Varian (VAR) Acquires Evinance to Boost Oncology Segment

                                        by Zacks Equity Research

                                        Varian Medical Systems (VAR) acquires Evinance to improve cancer care through CDS software. The company also expects to gain from flagship ARIA's recent certification.

                                          Zacks Equity Research

                                          Express Scripts, Walgreens Tie Up to Cut Specialty Drug Price

                                          by Zacks Equity Research

                                          Express Scripts (ESRX) expands group purchasing effort with Walgreens Boots Alliance to simplify supply chains and make specialty drugs affordable.

                                            Zacks Equity Research

                                            International Business Aids NuVasive, Pricing Woe Remains

                                            by Zacks Equity Research

                                            NuVasive (NUVA) plans to merge its U.S. Commercial and International sales functions into a global commercial organization. Also, several recent FDA approvals are encouraging.

                                              Zacks Equity Research

                                              Cerner Partnering With Surescripts to Revamp EHR Platform

                                              by Zacks Equity Research

                                              Cerner (CERN) will introduce Surescripts' Real-Time Prescription Benefit functionality into "Cerner Millennium's" EHR platform to help clients curtail escalating healthcare costs.

                                                Zacks Equity Research

                                                BD (BDX) Launches PAXgene in Europe for Advanced DNA Testing

                                                by Zacks Equity Research

                                                Becton, Dickinson and Company's (BDX) PAXgene ccfDNA gets a commercial launch in Europe and enables improved DNA testing in comparison to standard EDTA tubes.

                                                  Zacks Equity Research

                                                  NuVasive's SpineTRACK Registry Gains New CMS Designation

                                                  by Zacks Equity Research

                                                  NuVasive's (NUVA) receipt of the QCDR designation for its SpineTRACK buoys optimism for the stock. This achievement might add value to cushion its efforts to provide systems-based spine solutions.